Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | MIF | P14174 | 1/20 | 0.33 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MGAM | O43451 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | SI | P14410 | 1/20 | 0.31 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.31 |
| ▸ | TAS1R3 | Q7RTX0 | 4/20 | 0.31 |
| ▸ | TAS1R1 | Q7RTX1 | 4/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.30 |
| ▸ | CTSS | P25774 | 1/20 | 0.30 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8176228 | 0.85 | CAD (0.41) | SMN1; SMN2POLBMGAMGAASI | |
| SCHEMBL6005311 | 0.83 | CA1 (0.41) | CA1CA2BIRC2SMN1; SMN2ZDHHC7 | |
| SCHEMBL2702421 | 0.83 | MME (0.39) | CA1CA2SMN1; SMN2TAS1R3TAS1R1 | |
| SCHEMBL3486105 | 0.83 | MME (0.39) | CA1CA2SMN1; SMN2TAS1R3TAS1R1 | |
| SCHEMBL7495908 | 0.82 | ALDH1A1 (0.33) | CA1CA2SMN1; SMN2TAS1R3TAS1R1 | |
| SCHEMBL222755 | 0.80 | CA1 (0.52) | CA1CA2BIRC2ZDHHC7TAS1R3 | |
| SCHEMBL8609821 | 0.79 | TAS1R3 (0.45) | BIRC2SMN1; SMN2POLBTAS1R3TAS1R1 | |
| SCHEMBL8612400 | 0.79 | TSHR (0.36) | CA1CA2BIRC2SMN1; SMN2MGAM | |
| SCHEMBL3674350 | 0.77 | — | — | |
| SCHEMBL14591442 | 0.77 | CA1 (0.45) | CA1CA2BIRC2SMN1; SMN2MIF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1207161-B1 | NOVEL ISOINDOLE DERIVATIVES | BANYU PHARMA CO LTD (JP) | 2006-01-18 | — | — | EP | disclosed |
| US-6777410-B2 | SUCH AS 9-(2-METHOXYPHENYL)-3-(1-METHYLETHYL)-(1,3)OXAZOLO-(2,3)ISOINDOLE-2,5(3H,9H)-DIONE; DIABETES AND COMPLICATIONS; OBESITY | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-08-17 | — | — | US | disclosed |
| US-20040053923-A1 | Novel isoindole derivatives | BANYU PHARMACEUTICAL CO., LTD. | 2004-03-18 | — | — | US | disclosed |
| US-6608098-B1 | Diabetes or obesity, 2-(4-(3-isopropyl-2,5-dioxo-2,3-dihydro-1H-pyrrolo(2,1-a) isoindol-9(5H)-yl)phenoxy)-N-propylacetamide | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2003-08-19 | — | — | US | disclosed |
| EP-1207161-A1 | NOVEL ISOINDOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2002-05-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053923-A1 | Novel isoindole derivatives | GPR119, SLC5A2, SLC5A1 | CA1 3547/4885CA2 791/4885BIRC2 3698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.